Skip to main content

World AIDS Day 2012

© Syda Productions / stock.adobe.c1st December every year marks World AIDS Day and it is an opportunity not only to raise awareness of the disease, but to highlight the progress made by scientists and clinicians around the world to understand and find ways to cure the disease. At present, no cure or vaccine exists to combat the disease, but there have been strong advancements in our understanding of HIV and AIDS and the development of potential therapeutics. 

The articles below showcase the breadth and high calibre of the AIDS and HIV research published in our open access journals Retrovirology, BMC Infectious Diseases, AIDS Research and Therapy and Globalization and Health.

  1. December 1st marks World AIDS Day with the theme ‘Getting to zero’. Three years ago, UNAIDS articulated what was then considered to be an ambitious vision, the aspiration for zero new HIV infections and zero-A...

    Authors: Kent Buse, Ruth Blackshaw and Marie-Goretti Harakeye Ndayisaba
    Citation: Globalization and Health 2012 8:42
    Content type: Commentary Published on:

  2. Each year more than two million people are newly infected with HIV worldwide, a majority of them through unprotected vaginal sex. More than half of new infections in adults occur in women. Male condoms and mal...

    Authors: Jael Obiero, Peter G Mwethera, Gregory D Hussey and Charles S Wiysonge
    Citation: BMC Infectious Diseases 2012 12:289
    Content type: Research article Published on:

  3. The risk of HIV-1 related mortality is strongly related to CD4 count. Guidance on optimal timing for initiation of antiretroviral therapy (ART) is still evolving, but the contribution of HIV-1 infection to exc...

    Authors: Guy de Bruyn, Amalia Magaret, Jared M Baeten, Jairam R Lingappa, Patrick Ndase, Connie Celum and Anna Wald
    Citation: BMC Infectious Diseases 2012 12:277
    Content type: Research article Published on:

  4. A modest change in HIV-1 fitness can have a significant impact on viral quasispecies evolution and viral pathogenesis, transmission and disease progression. To determine the impact of immune escape mutations s...

    Authors: Hongshuo Song, Jeffrey W Pavlicek, Fangping Cai, Tanmoy Bhattacharya, Hui Li, Shilpa S Iyer, Katharine J Bar, Julie M Decker, Nilu Goonetilleke, Michael KP Liu, Anna Berg, Bhavna Hora, Mark S Drinker, Josh Eudailey, Joy Pickeral, M Anthony Moody…
    Citation: Retrovirology 2012 9:89
    Content type: Research Published on:

  6. The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment,...

    Authors: Kristof Theys, Koen Deforche, Jurgen Vercauteren, Pieter Libin, David AMC van de Vijver, Jan Albert, Birgitta Ã…sjö, Claudia Balotta, Marie Bruckova, Ricardo J Camacho, Bonaventura Clotet, Suzie Coughlan, Zehava Grossman, Osamah Hamouda, Andrzei Horban, Klaus Korn…
    Citation: Retrovirology 2012 9:81
    Content type: Research Published on:

  7. The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were su...

    Authors: Debby Basu, Colleen S Kraft, Megan K Murphy, Patricia J Campbell, Tianwei Yu, Peter T Hraber, Carmela Irene, Abraham Pinter, Elwyn Chomba, Joseph Mulenga, William Kilembe, Susan A Allen, Cynthia A Derdeyn and Eric Hunter
    Citation: Retrovirology 2012 9:76
    Content type: Research Published on:

  8. The true prevalence of HIV and other sexually transmitted diseases among street children in Nepal is virtually unknown while information on related behavioural risk factors in this population is non-existent. ...

    Authors: Dibesh Karmacharya, Dongmei Yu, Sameer Dixit, Rajesh Rajbhandari, Bhawana Subedi, Sonu Shrestha, Sulochana Manandhar and Susan L Santangelo
    Citation: AIDS Research and Therapy 2012 9:25
    Content type: Research Published on:

  9. Susceptibility to HIV-1 and the clinical course after infection show a substantial heterogeneity between individuals. Part of this variability can be attributed to host genetic variation. Initial candidate gen...

    Authors: Daniëlle van Manen, Angélique B van ‘t Wout and Hanneke Schuitemaker
    Citation: Retrovirology 2012 9:70
    Content type: Review Published on:

  10. Thymidine analogue resistance mutations (TAMs) selected under treatment with nucleoside analogues generate two distinct genotypic profiles in the HIV-1 reverse transcriptase (RT): (i) TAM1: M41L, L210W and T21...

    Authors: Gilberto Betancor, César Garriga, Maria C Puertas, María Nevot, Lourdes Anta, José L Blanco, M Jesús Pérez-Elías, Carmen de Mendoza, Miguel A Martínez, Javier Martinez-Picado and Luis Menéndez-Arias
    Citation: Retrovirology 2012 9:68
    Content type: Research Published on:

  11. Zambia’s national HIV testing algorithm specifies use of two rapid blood based antibody assays, Determine®HIV-1/2 (Inverness Medical) and if positive then Uni-GoldTM Recombigen HIV-1/2 (Trinity Biotech). Little i...

    Authors: Dalila Zachary, Lawrence Mwenge, Monde Muyoyeta, Kwame Shanaube, Albertus Schaap, Virginia Bond, Barry Kosloff, Petra de Haas and Helen Ayles
    Citation: BMC Infectious Diseases 2012 12:183
    Content type: Research article Published on:

  13. HIV-1 superinfection occurs at varying frequencies in different at risk populations. Though seroincidence is decreased, in the negative partner of HIV-discordant couples after joint testing and counseling in t...

    Authors: Colleen S Kraft, Debby Basu, Paulina A Hawkins, Peter T Hraber, Elwyn Chomba, Joseph Mulenga, William Kilembe, Naw H Khu, Cynthia A Derdeyn, Susan A Allen, Olivier Manigart and Eric Hunter
    Citation: Retrovirology 2012 9:22
    Content type: Research Published on:

  14. HIV spread continues at high rates from infected persons to their sexual partners. In 2009, an estimated 2.6 million new infections occurred globally. People living with HIV (PLHIV) receiving treatment are in ...

    Authors: Avina Sarna, Stanley Luchters, Melissa Pickett, Matthew Chersich, Jerry Okal, Scott Geibel, Nzioki Kingola and Marleen Temmerman
    Citation: AIDS Research and Therapy 2012 9:9
    Content type: Research Published on:

  15. Increased risk of fractures and osteoporosis have been associated with the use of antiretroviral drugs. There is a paucity of prospective evaluations of bone markers after the initiation of drugs currently rec...

    Authors: Emanuele Focà, Davide Motta, Marco Borderi, Daria Gotti, Laura Albini, Alessandra Calabresi, Ilaria Izzo, Rita Bellagamba, Pasquale Narciso, Laura Sighinolfi, Alberto Clò, Davide Gibellini, Eugenia Quiros-Roldan, Nigritella Brianese, Bruno Mario Cesana, Maria Carla Re…
    Citation: BMC Infectious Diseases 2012 12:38
    Content type: Research article Published on:

  16. HIV-1-infected elite controllers or suppressors (ES) maintain undetectable viral loads (< 50 copies/mL) without antiretroviral therapy. The mechanisms of suppression are incompletely understood. Modulation of ...

    Authors: Kenneth W Witwer, Andria K Watson, Joel N Blankson and Janice E Clements
    Citation: Retrovirology 2012 9:5
    Content type: Research Published on:

  17. The GNB3 C825T polymorphism is associated with increased G protein-mediated signal transduction, SDF-1α-mediated lymphocyte chemotaxis, accelerated HIV-1 progression, and altered responses to antiretroviral thera...

    Authors: Jennifer Juno, Jeffrey Tuff, Robert Choi, Catherine Card, Joshua Kimani, Charles Wachihi, Sandra Koesters-Kiazyk, T Blake Ball, Carey Farquhar, Francis A Plummer, Grace John-Stewart, Ma Luo and Keith R Fowke
    Citation: Retrovirology 2012 9:1
    Content type: Research Published on: